Previous 10 | Next 10 |
tonefotografia/iStock via Getty Images China-based biotech company I-Mab ([[IMAB]] -3.9%) has surged ~61.3% so far this year to outperform the broader market. However, a model update following upward revisions to earnings and multiple expansions has prompted Cantor Fitzgerald analyst Louise C...
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
TRACON Pharmaceuticals (TCON) presented promising data from the company’s Phase 1 study of uliledlimab ((TJ004309)) and Tecentriq (atezolizumab) at the American Society of Clinical Oncology ((ASCO)) virtual annual meeting.Uliledlimab was safe and well-tolerated up to 20 mg/kg every thr...
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharma...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
I-Mab Announces Upcoming Participation at June Conferences PR Newswire SHANGHAI and GAITHERSBURG, Md. , May 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and c...
Top Health Care Stocks To Watch In The Stock Market This Week Health care stocks are one of the most significant sectors in the stock market . In fact, health care was a defensive play even before the pandemic. But with more people infected with COVID-19 facing long-term health ...
MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential. Inclusion typically represents validation for a company’s products and outlook. MSCI says the index aims to represent the performance of large...
Shares of I-Mab (IMAB) are up 9.1% in morning trading after the company released favorable phase 1 safety and tolerability data on its monoclonal antibody uliledlimab.The dose-escalation trial showed no dose-limiting toxicities when uliledlimab was combined with Tecentriq ...
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 PR Newswire Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation t...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...